- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01461512
Heme Arginate in Functional Magnetic Resonance Imaging (fMRI)
The Effects of Intravenous Heme Arginate on Functional Magnetic Resonance Imaging During Ischemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Ischemia reperfusion injury may be attenuated by HO-1 induction. Heme arginate showed protective effects during prolonged ischemia in animal studies. The investigators previous data confirmed strong HO-1 induction following heme arginate infusion in healthy humans. Therefore, the investigators next approach is to evaluate the direct effects of heme arginate on short time Ischemia-reperfusion (IR) injury in healthy humans. This will be done by the following surrogate markers of IR injury.
Functional blood oxygen level dependent (BOLD) magnetic resonance imaging (MRI) can measure alterations in tissue oxygenation in a high spatial and temporal resolution. This non-invasive methods therefore represent a promising technique to evaluate the effects of HO-1 induction on energy metabolism and oxygen saturation during ischemic stress and short time reperfusion in skeletal muscle.
As additional outcome, levels of myoglobin and creatine-kinase will be measured in plasma according to standard laboratory procedures.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Medical University of Vienna, Department of Clinical Pharmacology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Men aged between 18 and 46 years (inclusive)
- Nonsmoker for more than 3 months
- Body mass index between 18 and 27 kg/m2
- Normal findings in medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
- Negative results from urine drug screen if performed
- Ability to communicate well with the investigator in the local language and to understand and comply with the requirements of the study
Exclusion Criteria:
- Known hypersensitivity to the study drug or any excipients of the drug formulation
- Regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study
- Treatment with another investigational drug within 3 weeks prior to screening
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
- Evidence of hypertension, pathologic hyperglycemia, hyperlipidemia
- Treatment in the previous 3 weeks with any drug including over-the-counter drugs (including herbal medicines such as St John's Wort)
- Symptoms of a clinically relevant illness in the 2 weeks before the first study day
- Blood donation during the previous 3 weeks
- Any metallic, electric, electronic or magnetic device or object not removable
- Claustrophobia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
NaCl isotonic
|
Experimental: Heme arginate treatment
|
heme arginate 1 mg/kg body weight 24 hours prior to ischemia
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BOLD MRI signal
Time Frame: 2 minutes prior to ischemia till 25 minutes after ischemia
|
functional MRI assessment of blood oxygen level dependent signal strength
|
2 minutes prior to ischemia till 25 minutes after ischemia
|
Serum markers of myocellular injury
Time Frame: 24 hours after ischemia
|
(myoglobin, creatine-kinase)
|
24 hours after ischemia
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood pressure
Time Frame: 20 minutes prior to and 40 minutes after ischemia
|
in mmHg
|
20 minutes prior to and 40 minutes after ischemia
|
Heart rate
Time Frame: prior to and after ischemia
|
in beats per minute
|
prior to and after ischemia
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version 1.2 2008-006967-35
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemia-reperfusion Injury
-
University of ChileFondo Nacional de Desarrollo Científico y Tecnológico, ChileCompletedReperfusion Injury | Acute Myocardial Infarction | Ischemia-reperfusion Injury | Reperfusion Injury, Myocardial | Reperfusion ArrhythmiasChile
-
University of AarhusErasmus Medical Center; Fonden til Lægevidenskabens FremmeCompletedIschemia Reperfusion Injury | Ischaemia Reperfusion InjuryDenmark
-
Samsung Medical CenterCompletedIschemia/Reperfusion Injury of Liver Graft | Ischemia/Reperfusion Injury of Kidney | Remote Ischemic PostconditioningKorea, Republic of
-
Shahid Beheshti University of Medical SciencesPooyesh DarouCompletedMyocardial Ischemic Reperfusion InjuryIran, Islamic Republic of
-
Tambi JarmiWithdrawn
-
University of PennsylvaniaActive, not recruiting
-
José García de la AsunciónCompleted
-
Medical University InnsbruckUnknownIschemia Reperfusion Injury
-
Aristotle University Of ThessalonikiCompletedIschemia Reperfusion Injury
-
University of ZurichUnknownIschemia/Reperfusion InjurySwitzerland
Clinical Trials on Placebo administration
-
Camilo Jose Cela UniversityCompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRIActive, not recruiting
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRICompleted
-
J2H BiotechCompletedNon-alcoholic SteatohepatitisKorea, Republic of
-
M.D. Anderson Cancer CenterTerSera Therapeutics LLCRecruitingLocally Advanced Neuroendocrine Neoplasm | Metastatic Neuroendocrine NeoplasmUnited States
-
John Paul II Hospital, KrakowNational Center for Research and Development, Poland; KCRICompleted
-
OculisNeurotrialsRecruitingOptic Neuritis | Optic; Neuritis, With DemyelinationFrance
-
PurGenesis Technologies Inc.CompletedAtopic Dermatitis EczemaCanada
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)WithdrawnGlioma | Ependymoma | Medulloblastoma | Pineoblastoma | Central Nervous System Sarcoma | Primary Central Nervous System Neoplasm | Malignant Intracranial Germ Cell TumorUnited States